Compliance with drug therapies for the treatment and prevention of osteoporosis

Maturitas

Volumn 48, Issue 3, 2004, Pages 271-287

  McCombs, Jeffrey S ^a   Thiebaud, Patrick ^a   McLaughlin Miley, Connie ^b   Shi, Jinhai ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b AMGEN INC   (United States)

Author keywords

Estrogen; Health care costs; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIRHEUMATIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; GESTAGEN; MEDROXYPROGESTERONE ACETATE; NONSTEROID ANTIINFLAMMATORY AGENT; NORETHISTERONE; NORETHISTERONE ACETATE; PIPERAZINE ESTRONE SULFATE; RALOXIFENE; RISEDRONIC ACID; STEROID; VITAMIN D;

ADULT; AGED; ARTICLE; COLLES FRACTURE; DRUG EFFICACY; FEMALE; FRAGILITY FRACTURE; HEALTH CARE COST; HEALTH INSURANCE; HEALTH SERVICE; HIP FRACTURE; HORMONE SUBSTITUTION; HOSPITAL CARE; HOSPITAL CHARGE; HUMAN; MALE; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; OUTPATIENT CARE; PATIENT COMPLIANCE; RISK ASSESSMENT; VERTEBRA FRACTURE;

AGE FACTORS; AGED; AGED, 80 AND OVER; DIPHOSPHONATES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FRACTURES, BONE; HEALTH CARE COSTS; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OSTEOPOROSIS; PATIENT COMPLIANCE; RALOXIFENE; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 2942672302     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2004.02.005     Document Type: Article

References (25)

1. America's Bone Health: The State of Osteoporosis and Low Bone Mass. NOF: National Osteoporosis Foundation. 2002 Report. http://www.nof.org.
2. Melton L.J., Chrischilles E.F., Cooper C., Lane A.W., Riggs B.L. How many women have osteoporosis? J Bone Miner. Res. 7(9):1992;1005-1010
3. Martin B.C., Chisholm M.A., Kotzan J.A. Isolating the cost of osteoporosis-related fractures for postmenoposal women. Gerontology. 47:2001;21-29
4. Lindsay R. The burden of osteoporosis: cost. Am J Med. 98(2A):1995;9S-11S
5. Ray N.F., Chan J.K., Thamer M., Melton L.J. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: Report from the National Osteoporosis Foundation. J Bone Miner. Res. 12(1):1997;24-35
6. Cooper C. The crippling consequence of fractures and their impact on quality of life. Am J Med. 103(2A):1997;13S-15S
7. Seeman E. Osteoporosis: trials and tribulations. Am J Med 1997;103(2A) Supplement 18:74S-87S.
8. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med. 98(2A):1995;3S-7S
9. Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med. 103(2A):1997;20S-25S
10. Brainsky A., Glick H., Lydick E., Epstein R., Fox K.M., Hawkes W., et al. The economic cost of hip fractures in community-dwelling older adults: a prospective study. J Am Geriatr Soc. 45(3):1997;281-287
11. Cummins S.R., Rubin S.M., Black D. The future of hip fractures in the United States. Clin. Orthop. 252:1990;163-166
12. Kotzan J.A., Martin B.C., Wade W.E. Persistence with estrogen therapy in a postemenoposal Medicaid Population. Pharmacotherapy. 19(3):1999;363-369
13. Cano A. Compliance to hormone replacement therapy in menopausal women controlled in a third level academic center. Maturitas. 20(2-3):1994;91-99
14. Faulkner D.L., Young C., Hutchins D., McCollam J.S. Patient noncompliance with hormone replacement therapy: a nationwide estimate using a large prescription claims database. Menopause. 5(4):1998;226-229
15. Cole R.P., Palushock S., Haboubi A. Osteoporosis management: physician's recommendations and women's compliance following osteoporosis testing. Women Health. 29(1):1999;101-115
16. Kayser J., Ettinger B., Pressman A. Postmenopausal hormonal support: discontinuation of raloxifene versus estrogen. Menopause. 8(5):2001;328-332
17. Marwick C. Hormone combination treats women's bone loss. J. Am. Med. Assoc. 272(19):1994;1487
18. Bjorn I., Backsrom T. Drug related negative side-effects is a common reason for poor compliance with hormone replacement therapy. Maturitas. 32(2):1999;77-86
19. Ettinger B., Li D.K., Klein R. Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation. J Managed Care Pharmacy. 4(5):1998;488-492
20. Office of Technology Assessment, United States Congress. Effectiveness and costs of osteoporosis screening and hormone replacement therapy, volumes I and II. OTA-BP-H-160, Washington, DC: US Government Printing Office; August 1995.
21. Women's health initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002;288(3):321-33.
22. Duan N., Manning W.G., Morris C.N., Newhouse J.P. A comparison of alternative models for the demand of medical care. J Bus Econ Stat. 1(2):1983;115-126
23. SAS/STAT User's Guide, Version 8, volume 2. Cary NC: SAS Institute Inc.; 1999 [Chapter 36].
24. Cohen F.J., Lu Y. Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials. Maturitas. 34:1999;65-73
25. O'Regan R.M., Gradishar W.J. Selective estrogen-receptor modulators in 2001. Oncology. 15(9):2001;1177-1194